These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31905715)

  • 1. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.
    Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
    Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
    Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.
    Tylki-Szymańska A; Almássy Z; Christophidou-Anastasiadou V; Avdjieva-Tzavella D; Barisic I; Cerkauskiene R; Cuturilo G; Djiordjevic M; Gucev Z; Hlavata A; Kieć-Wilk B; Magner M; Pecin I; Plaiasu V; Samardzic M; Zafeiriou D; Zaganas I; Lampe C
    Orphanet J Rare Dis; 2022 Mar; 17(1):136. PubMed ID: 35331284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
    Chen HH; Sawamoto K; Mason RW; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Tomatsu S
    J Hum Genet; 2019 Nov; 64(11):1153-1171. PubMed ID: 31455839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
    Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
    Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II.
    Hoshina H; Shimada Y; Higuchi T; Kobayashi H; Ida H; Ohashi T
    Mol Genet Metab; 2018 Feb; 123(2):118-122. PubMed ID: 29289480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbohydrate-Processing Enzymes of the Lysosome: Diseases Caused by Misfolded Mutants and Sugar Mimetics as Correcting Pharmacological Chaperones.
    Stütz AE; Wrodnigg TM
    Adv Carbohydr Chem Biochem; 2016; 73():225-302. PubMed ID: 27816107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucopolysaccharidosis III: Molecular basis and treatment.
    Spahiu L; Behluli E; Peterlin B; Nefic H; Hadziselimovic R; Liehr T; Temaj G
    Pediatr Endocrinol Diabetes Metab; 2021; 27(3):201-208. PubMed ID: 34743503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets.
    Leal AF; Benincore-Flórez E; Rintz E; Herreño-Pachón AM; Celik B; Ago Y; Alméciga-Díaz CJ; Tomatsu S
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn screening of mucopolysaccharidoses: past, present, and future.
    Arunkumar N; Langan TJ; Stapleton M; Kubaski F; Mason RW; Singh R; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
    J Hum Genet; 2020 Jul; 65(7):557-567. PubMed ID: 32277174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased Levels of Chaperones in Mucopolysaccharidoses and Their Elevation as a Putative Auxiliary Therapeutic Approach.
    Żabińska M; Gaffke L; Bielańska P; Podlacha M; Rintz E; Cyske Z; Węgrzyn G; Pierzynowska K
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
    Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
    PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucopolysaccharidoses and mucolipidoses.
    Van Hoof F
    J Clin Pathol Suppl (R Coll Pathol); 1974; 8():64-93. PubMed ID: 4220223
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacological chaperones as therapeutics for lysosomal storage diseases.
    Boyd RE; Lee G; Rybczynski P; Benjamin ER; Khanna R; Wustman BA; Valenzano KJ
    J Med Chem; 2013 Apr; 56(7):2705-25. PubMed ID: 23363020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression-targeted isoflavone therapy.
    Węgrzyn A
    IUBMB Life; 2012 Apr; 64(4):307-15. PubMed ID: 22362546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
    Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.
    Valenzano KJ; Khanna R; Powe AC; Boyd R; Lee G; Flanagan JJ; Benjamin ER
    Assay Drug Dev Technol; 2011 Jun; 9(3):213-35. PubMed ID: 21612550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.